Clinical trial · Interventional
Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas
NCT06914674CI-TRIAL-00088193SPTPrecruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Tamoxifen for Solid Pseudopapillary Tumor of the Pancreas
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Neoplasms | Pancreatic Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Tamoxifen 20 mg | Drug | Tamoxifen | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Tamoxifen
- description
- Tamoxifen: 10 mg orally twice daily. Combination therapy: Chemotherapy, radiotherapy, surgery, or other treatments per NCCN guidelines and patient condition.
- interventionNames
- Drug: Tamoxifen 20 mg
Primary outcomes (1)
- measure
- Progression-free survival (PFSn)
- timeFrame
- 1 month
- description
- Time from enrollment to disease progression
Secondary outcomes (2)
- measure
- Overall survival （OS）
- timeFrame
- 1 month
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 14 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age 14-80 years. 2. Histologically confirmed advanced SPTP with ER/PR+. 3. Advanced disease: * Unresectable primary tumor or distant metastasis (liver, lung, peritoneum, etc.). * Recurrent or refractory after prior surgery/systemic therapy. 4. ≥1 measurable lesion. 5. ECOG performance status 0-2. 6. Life expectancy ≥1 month. 7. Able to comply with study visits and oral medication. Exclusion Criteria: 1. Non-SPTP pathology. 2. Active gastrointestinal inflammation/infection (e.g., pancreatitis). 3. Pregnancy/lactation. 4. Severe organ dysfunction (renal, cardiac, hepatic, or pulmonary). 5. Uncontrolled comorbidities (e.g., CNS disorders, unstable angina). 6. Conditions compromising patient safety or data integrity.
References
Publications (4)
- BACKGROUNDKornietskaya A, Evdokimova S, Kachmazov A, Fedenko A, Bolotina L, Sidorov D, Volchenko N, Goeva N, Govaleshko A, Kaprin A. Endocrine therapy for metastatic solid pseudopapillary neoplasm of the pancreas: A case report. Front Oncol. 2022 Sep 13;12:970142. doi: 10.3389/fonc.2022.970142. eCollection 2022. PMID 36176411
- BACKGROUNDGuo M, Luo G, Jin K, Long J, Cheng H, Lu Y, Wang Z, Yang C, Xu J, Ni Q, Yu X, Liu C. Somatic Genetic Variation in Solid Pseudopapillary Tumor of the Pancreas by Whole Exome Sequencing. Int J Mol Sci. 2017 Jan 3;18(1):81. doi: 10.3390/ijms18010081. PMID 28054945
- BACKGROUNDNishihara K, Tsuneyoshi M, Ohshima A, Yamaguchi K. Papillary cystic tumor of the pancreas. Is it a hormone-dependent neoplasm? Pathol Res Pract. 1993 Jun;189(5):521-6. doi: 10.1016/S0344-0338(11)80359-6. PMID 8378176
- BACKGROUNDDominguez-Rosado I, Chan C, Ortiz-Hidalgo C, Chable-Montero F, Uscanga LF, Campuzano M, Robles-Diaz G. Immunohistochemical expression of luteinizing hormone receptor in solid pseudopapillary tumor of the pancreas. Pancreas. 2014 Aug;43(6):971-2. doi: 10.1097/MPA.0000000000000134. No abstract available. PMID 25010708